UCSF May Submit 1 Application to each RFA

Internal Deadline: 11:59 PM, Monday, September 24th, 2018

PLEASE FORWARD THIS ANNOUNCEMENT TO ALL APPROPRIATE FACULTY AND RESEARCH ADMINISTRATORS

Please Note: This announcement includes details for two companion opportunities

WHAT:


REQUEST FOR APPLICATIONS NUMBERS:
CP-CTNet Sites: RFA-CA-18-029
Data Management, Auditing, and Coordinating Center: RFA-CA-18-030

PURPOSE:
- To support the Cancer Prevention Clinical Trials Network (CP-CTNet), for which the goals are as follows:
  - Design and conduct of early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (micro-dosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials.
  - Characterization of the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlation of these effects with clinical endpoints.
  - Development of further scientific insights into the mechanisms of cancer prevention by the agents examined, including the development of novel potential markers as determinants of response.
- CP-CTNet consists of two types of components:
  - Five CP-CTNet Sites
  - One CP-CTNet Data Management, Auditing, and Coordinating Center (DMACC)
- The CP-CTNet Sites will provide scientific leadership in development and conduct of early phase cancer prevention clinical trials as well as in the management and analysis of the data.
- The DMACC will support the CP-CTNet Sites and coordinate trans-Network activities with the following specific responsibilities:
  - (i) centralized data management and data reporting,
  - (ii) clinical trials auditing, and
  - (iii) administrative and logistical coordination across CP-CTNet.
ELIGIBILITY:

- **Sites:** PIs are expected to be nationally and internationally recognized leaders in clinical trials of cancer preventive agents. This expertise should reflect mainly clinical trials of preventive agents (e.g., drugs, small molecules, vaccines/biologics) using measures of drug action and efficacy that include modulation of cancer-related biomarkers. Additional expertise in other cancer preventive approaches (including medical devices, cancer preventive surgery, risk-reducing surgery, and non-surgical ablative techniques) is also desirable.

- **DMACC:** PIs are expected to be nationally and internationally recognized leaders in management and stewardship of network-based/multicenter clinical trials. Their expertise should broadly encompass the three functional areas of DMACC activities, viz., data management and reporting, clinical trials auditing, and administrative and logistical coordination. It is expected that the PDs/PIs lead a multi-disciplinary team comprised of domain-specific experts with substantial experience in leading each of the three functional areas of the CP-CTNet DMACC.

BUDGET AND PROJECT PERIOD:

- **Sites:**
  - Award Budget: The requested budget must not exceed $625,000 in direct costs for year 1 and $1,250,000 in direct costs for subsequent years.
    - UCSF indirect cost policy will apply except for non-federal entities.
  - Project Period: 5 years

- **DMACC:**
  - Award Budget: The requested budget must not exceed $1.25M in direct costs for year 1 and $1.90M in direct costs for subsequent years.
    - UCSF indirect cost policy will apply except for non-federal entities.
  - Project Period: 5 years

NUMBER OF APPLICATIONS UCSF MAY SUBMIT: UCSF may submit one application to each RFA, but the PDs/PIs of applications submitted in response to one RFA must not be named as Senior/Key Personnel or Other Significant Contributors on any teams submitting applications to the companion RFA.

APPLICATION TYPES ALLOWED: New

DUE DATES:

- **Internal:** 11:59 PM, Monday, September 24th, 2018. If multiple groups submit an LOI, an additional pre-application will be due Tuesday, October 2nd.
- Please note PIs may submit directly to the LSP; RMS does not get involved unless and until you are nominated
- **Sponsor:** Thursday, November 15th, 2018.

Submit the attached Letter of Intent (LOI) by 11:59 PM, September 24th, 2018, to: limitedsubmissions@ucsf.edu

To qualify for UCSF Limited Submission Program opportunities, applicants must have a paid UCSF appointment either at the time of application or anticipated by the time of award.
The LSP is a selection process, not an award process. As the LSP is under significant time constraints, all reviewer feedback is optional. We encourage you to seek other avenues for proposal feedback.

For information on all current LSOs, please visit: http://rdo.ucsf.edu/limited-submission-program-lsp

Sent by Lisa Howard on behalf of the Research Development Office (RDO), Limited Submission Program (LSP)